Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Neurol Neurosurg ; 226: 107610, 2023 03.
Article in English | MEDLINE | ID: covidwho-2177632

ABSTRACT

BACKGROUND: We investigated the prevalence of headache, migraine, and medication-overuse headache (MOH) among children and adolescents through a school-based online questionnaire. We also investigated the triggers for migraine among them and the effect of the COVID-19 pandemic on headache frequency. METHODS: Children and adolescents aged 6-17 y.o. completed an online questionnaire. Migraine, MOH was defined as The International Classification of Headache Disorders Third edition. Factor and clustering analyses were performed for migraine triggers. The effect of the coronavirus disease 2019 (COVID-19) pandemic on headache frequency was also asked. RESULTS: Of the 2489 respondents, the prevalence of headache, migraine, and MOH were 36.44%, 9.48%, and 0.44%, respectively. Up to 70% of the respondents with headaches complained of the disturbance to daily life, but about 30% consulted doctors. The migraine triggers were grouped into 5 factors by factor analysis. The sensitivities of the migraineurs against the factors were divided into 3 clusters. Cluster 1 had stronger sensitivity for several triggers. Cluster 2 was sensitive to weather, smartphones, and video games. Cluster 3 had less sensitivity for triggers. Cluster 2 less consulted doctors even though the burden of migraine was enormous. During the COVID-19 pandemic, 10.25% of respondents increased headache attacks, while 3.97% decreased. CONCLUSIONS: This is the first detailed study on headache prevalence in Japanese students from elementary school to high school in one region. The burden of headaches is large among children and adolescents, and the unmet needs of its clinical practice should be corrected.


Subject(s)
COVID-19 , Headache Disorders, Secondary , Headache Disorders , Migraine Disorders , Humans , Adolescent , Child , Prevalence , Pandemics , East Asian People , COVID-19/epidemiology , Migraine Disorders/epidemiology , Headache/epidemiology , Headache Disorders, Secondary/epidemiology , Surveys and Questionnaires
2.
Neurol Sci ; 43(6): 3811-3822, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1633886

ABSTRACT

OBJECTIVE: The medication-overuse headache (MOH) prevalence has not been investigated in a general Japanese population. We performed questionnaire-based survey and revealed MOH prevalence and its characteristics. We also performed clustering to obtain insight for MOH subgrouping. METHODS: In this cross-sectional study, the 15-64-year-old population was investigated in Itoigawa during their COVID-19 vaccination under the national policy. MOH was defined as ≥ 15 days/month plus self-report of use of pain medications ≥ 10 or 15 days/month in the last 3 months. Ward method and k-means + + were used to perform clustering MOH patients. RESULTS: Among 5865 valid responses, MOH prevalence was 2.32%. MOH was common among females and the middle-aged. Combination-analgesic is the most overused as 50%. MOH had aggravation by routine physical activity, moderate or severe pain, and migraine-like, compared to non-MOH. The 136 MOH patients could be grouped into 3 clusters. Age and frequency of acute medication use were essential factors for clustering. CONCLUSIONS: This is the first study of MOH prevalence in Japan. Most MOH characteristics were similar to previous reports worldwide. Public awareness of proper headache treatment knowledge is still needed. Clustering results may be important for subtype grouping from a social perspective apart from existing clinical subtypes.


Subject(s)
COVID-19 , Headache Disorders, Secondary , Adolescent , Adult , Analgesics/adverse effects , COVID-19/epidemiology , COVID-19 Vaccines , Cross-Sectional Studies , Female , Headache/epidemiology , Headache Disorders, Secondary/epidemiology , Humans , Japan/epidemiology , Middle Aged , Prevalence , Surveys and Questionnaires , Young Adult
3.
J Headache Pain ; 22(1): 41, 2021 May 21.
Article in English | MEDLINE | ID: covidwho-1238702

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) bring about a range of psychological distress and symptom deterioration to headache patients especially to some migraineurs. Compared to migraineurs or normal control, medication overuse headache (MOH) patients are more likely to experience a worse psychological distress and poorer outcome in non-COVID-19 time. However, in COVID-19 pandemic, whether MOH patients would have greater physical and mental symptom deterioration or worse relief of headache symptoms and medications overuse remained unclear. We aim to investigate the impact of COVID-19 on MOH patients to guide for a better management in this study. METHODS: We enrolled MOH patients who were diagnosed and treated at headache clinic of West China Hospital. Information of the pre-pandemic 3 months period and COVID-19 pandemic period was collected. Univariate and multivariate logistic regression were performed to identify independent factors associated with changes in headache symptoms and drug withdrawal. RESULTS: Seventy-eight MOH patients were enrolled into the study ultimately. In comparison to pre-pandemic period, fewer MOH patients reported decreased headache days, intensity and days with acute medications per month during the pandemic. Available access to regular prophylactic medications was significantly associated with a reduction of at least 50% in headache days and decrease in headache intensity per month with respective odds ratios of 39.19 (95% CI 3.75-409.15, P = 0.002) and 10.13 (95% CI 2.33-44.12, P = 0.002). Following abrupt withdrawal and high educational level were both significant factors in decreasing headache intensity. Male sex was significantly associated with decrease in days with acute medication per month during the pandemic (odds ratios 4.78, 95%CI 1.44-15.87, P = 0.011). CONCLUSIONS: Our findings reflect that MOH patients experienced a worse relief of headache symptoms and drug withdrawal during the pandemic. Available access to regular prophylactic medications was the significant independent factor for improvement of headache symptoms. Male sex was significantly associated with decreased days with acute medications per month.


Subject(s)
COVID-19 , Headache Disorders, Secondary , Pharmaceutical Preparations , Analgesics/adverse effects , China/epidemiology , Cross-Sectional Studies , Headache , Headache Disorders, Secondary/epidemiology , Humans , Male , Pandemics , SARS-CoV-2
5.
Headache ; 60(8): 1788-1792, 2020 09.
Article in English | MEDLINE | ID: covidwho-714357

ABSTRACT

Headache was reported in up to one-third of the hospitalized patients; yet, the clinical characteristics of headache associated with coronavirus disease 2019 (COVID-19) have not been defined. This observational case study included patients who were consulted to headache unit due to headache and had COVID-19 illness. Headache features in 13 PCR-confirmed COVID-19 patients with mild symptoms were reported. Headache was the isolated symptom of the COVID-19 in 3 patients and emerged as an early symptom during the disease course in all patients. Patients specified severe, rapid onset, unrelenting headache with migraine-like features, as well as unusual sensory symptoms such as anosmia, and gastrointestinal symptoms such as diarrhea and loss of appetite and weight. Headache lasted up to 3 days in 70% of the patients and resolved in all patients within 2 weeks. Despite the fact that most of the patients were female and headache characteristics were suggestive of migraine, majority of patients were not suffering from primary headaches. It was concluded that headache could be an isolated symptom of COVID-19, which might possibly be ignored in asymptomatic patients. Headaches associated with COVID-19 included features resembling migraine and/or atypical symptoms including anosmia and diarrhea.


Subject(s)
COVID-19/complications , Headache Disorders, Secondary/etiology , Pandemics , SARS-CoV-2 , Adult , Anorexia/etiology , Asymptomatic Infections , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing , Diagnosis, Differential , Diarrhea/etiology , Female , Headache Disorders, Secondary/epidemiology , Humans , Male , Middle Aged , Migraine Disorders/diagnosis , Sensation Disorders/etiology , Symptom Assessment , Weight Loss
6.
Headache ; 60(8): 1664-1672, 2020 09.
Article in English | MEDLINE | ID: covidwho-713377

ABSTRACT

OBJECTIVE: In this study, we aimed to evaluate the frequency of the main red flags in patients with headache who do have Covid-19. BACKGROUND: Headache is one of the most frequent neurologic symptoms of Coronavirus disease 2019 (Covid-19). Diagnosis of secondary headache disorders is still based on the presence of red flags. DESIGN AND METHODS: Cross-sectional study of hospitalized patients with confirmed Covid-19 disease. We interrogated every patient about the presence of headache and if so, a headache expert conducted a structured interview assessing the presence and type of the main red flags. We evaluated the presence of laboratory abnormalities on admission. RESULTS: We screened 576 consecutive patients, 130/576 (22.6%) described headache, and 104 were included in the study. Mean age of patients was 56.7 (standard deviation: 11.2) and 66/104 (63.4%) were female. Red flags concerning prior medical history were present in 79/104 (76.0%) cases, and those related to the headache itself were observed in 99/104 (95.2%) patients. All patients 104/104 (100%) described systemic symptoms and 86/104 (82.7%) some neurologic symptoms. Laboratory results were abnormal in 98/104 (94.2%) cases. The most frequent red flags were fever, in 93/104 (89.4%) patients, cough, in 89/104 (85.6% cases), and increased C-reactive protein in 84/100 (84.0%) cases. CONCLUSION: In patients with Covid-19 that described the headache red flags were present in most cases. There was not any universal red flag, being necessary the comprehensive evaluation of all of them.


Subject(s)
C-Reactive Protein/analysis , COVID-19/complications , Cough/etiology , Fever/etiology , Headache Disorders, Secondary/etiology , Inpatients , Nervous System Diseases/etiology , SARS-CoV-2 , Age Factors , Aged , Biomarkers , COVID-19/blood , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing/methods , Cardiovascular Diseases/epidemiology , Comorbidity , Cross-Sectional Studies , Diabetes Mellitus/epidemiology , Exanthema/etiology , Female , Gastrointestinal Diseases/etiology , Headache/epidemiology , Headache Disorders, Secondary/blood , Headache Disorders, Secondary/diagnosis , Headache Disorders, Secondary/epidemiology , Hospitalization , Humans , Male , Middle Aged , Pain/etiology , Spain/epidemiology , Symptom Assessment
7.
Headache ; 60(8): 1697-1704, 2020 09.
Article in English | MEDLINE | ID: covidwho-645752

ABSTRACT

BACKGROUND: Series of patients with SARS-CoV-2 infection report headache in 6%-15% of cases, although some data suggest that the actual frequency is higher, and that headache is not associated with fever. No study published to date has analyzed the characteristics of headache in these patients. OBJECTIVE: To analyze the characteristics of COVID-19 related headaches. METHODS: We conducted a survey of Spaniard healthcare professionals who have been infected by SARS-CoV-2 and presented headache during the course of the disease. The survey addressed respondents' medical history and headache characteristics, and we analyzed the association between both. RESULTS: We analyzed the responses of a sample of 112 healthcare professionals. History of migraine was reported by 20/112 (17.9%) of respondents, history of tension-type headache by 8/112 (7.1%), and history of cluster headache was reported by a single respondent; 82/112(73.2%) of respondents had no history of headache. Headache presented independently of fever, around the third day after symptom onset. The previous history of migraine was associated with a higher frequency of pulsating headache (20% in patients with previous migraine vs 4.3% in those with no history of migraine, P = .013). CONCLUSION: Headache is often holocranial, hemicranial, or occipital, pressing, and worsens with physical activity or head movements. Because the characteristics of the headache and the associated symptoms are heterogeneous in our survey, we suggest that several patterns with specific pathophysiological mechanisms may underlie the headache associated with COVID-19.


Subject(s)
COVID-19/epidemiology , Headache/epidemiology , Health Personnel , SARS-CoV-2 , Adult , COVID-19/complications , Comorbidity , Cross-Sectional Studies , Diabetes Mellitus/epidemiology , Dyslipidemias/epidemiology , Female , Gastrointestinal Diseases/etiology , Headache/classification , Headache Disorders, Secondary/diagnosis , Headache Disorders, Secondary/epidemiology , Headache Disorders, Secondary/etiology , Humans , Hypertension/epidemiology , Male , Middle Aged , Migraine Disorders/epidemiology , Occupational Diseases/epidemiology , Pandemics , Personal Protective Equipment , Prevalence , Sensation Disorders/etiology , Spain/epidemiology , Surveys and Questionnaires , Tension-Type Headache/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL